SmithKline will pursue penciclovir switch "immediately" after Rx approval, CEO says.
This article was originally published in The Tan Sheet
SMITHKLINE WILL PURSUE PENCICLOVIR SWITCH "IMMEDIATELY" AFTER Rx APPROVAL, CEO Jan Leschly told securities analysts at Bear Stearns' annual health care conference on Sept. 9-11 in New York City. Leschly predicted that the "real potential" for the topical cold sore medication is as an over-the-counter product. He noted that "25% of the population suffer from cold sores."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC